At its June 12, 2026 annual meeting, Abeona Therapeutics Inc. stockholders approved increasing the shares reserved for issuance under the Second Amended and Restated 2023 Equity Incentive Plan from 8,400,000 to 11,500,000. Stockholders elected Keith A. Goldan and Bernhardt G. Zeiher, M.D. as Class 1 directors, ratified Deloitte & Touche LLP as the independent auditor, and approved executive compensation. A proposal to remove the advance notice provision for director nominations from the Amended and Restated Certificate of Incorporation failed to receive the required 66 2/3% affirmative vote. The company is a biopharmaceutical company that develops gene therapies.

Michael Amoroso resigned from the Board of Directors and the Nominating and Corporate Governance Committee of Abeona Therapeutics Inc. effective June 11, 2026, citing personal reasons. Abeona Therapeutics Inc. is a biotechnology company focused on developing gene and cell therapies.